Research programme: matrix metalloprotease inhibitors - LEO PharmaAlternative Names: matrix metalloprotease inhibitors research programme - LEO Pharma
Latest Information Update: 13 May 2003
At a glance
- Originator LEO Pharma
- Mechanism of Action Matrix metalloproteinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 May 2003 Discontinued - Preclinical for Cancer in Denmark (unspecified route)
- 19 Sep 2002 Preclinical trials in Cancer in Denmark (unspecified route)